TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:~1. Age 18-80 at screening (or minimum age of consent according to local regulations).~2 Chronic AD (also known as atopic eczema) that was diagnosed at least 1 year prior to Screening and meets Hanifin and Rajka criteria at screening).1 3. Moderate to severe AD:~1. IGA score ≥3 (on the 0 to 4 IGA scale, in which 3 = moderate and 4 = severe) at screening and baseline (Day 1)~2. BSA ≥10% of AD involvement at screening and baseline (Day 1)~3. Eczema Area and Severity Index (EASI) ≥16 at screening and baseline (Day 1) 4. A participant who has failed a prior systemic therapy for AD, ie, refractory, moderate-to-severe AD that is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.~   5. Willing to apply a topical emollient/moisturizer at least once daily for ≥1 week prior to baseline (Day 1) and willing to maintain consistent (ie, no change in type, frequency, or application) daily application over the course of the study.~   Exclusion Criteria:~   Participants are excluded from the study if any of the following criteria apply:~   Medical Conditions:~  1. Presence of confounding factors:~      * Skin conditions (eg, psoriasis, seborrheic dermatitis) that may interfere with evaluation of AD or assessment of treatment response as deemed by the investigator.~     * Current significant active infection or requiring a treatment for infection that may interfere with the assessment of AD.~  2. Hypersensitivity to etrasimod or any of the excipients.~  3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- etrasimod (Type: EXPERIMENTAL): 2 mg, oral tablet, once daily
- Placebo (Part 1 DB period only) (Type: PLACEBO_COMPARATOR): Oral sham comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed melanoma, either unresectable stage IIIc or stage IV metastatic melanoma, as defined by AJCC 7th edition.~* Patients must be naïve to treatment for locally advanced unresectable or metastatic disease. Prior immunotherapy (including ipilimumab) is allowed.~* Documentation of BRAFV600E or BRAFV600K mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples).~* Measurable disease per RECIST v1.1, which are accessible to biopsies.~* Biopsy lesion is within scan reach of diagnostic CT and PET-CT (thorax- abdomen-pelvis)~* ECOG performance status of 0 or 1.~* Male or female patient aged ≥ 18 years.~* Life expectancy ≥ 12 weeks.~* Adequate hematologic and end organ function within 14 days prior to first dose of study drug treatment.~Exclusion Criteria:~* History of prior RAF or MEK pathway inhibitor treatment.~* Palliative radiotherapy, major surgery or traumatic injury within 14 days prior to the first dose of study treatment.~* Active malignancy within the past 3 years other than melanoma that could potentially interfere with the interpretation of efficacy measures, except for patients with resected BCC or SCC of the skin, melanoma in-situ, carcinoma in-situ of the cervix, and carcinoma in-situ of the breast.~* History of or evidence of retinal pathology, clinically significant cardiac dysfunction, patients with active CNS lesions, renal or liver dysfunction as described in main protocol (REPOSIT NL48639.031.14).~* Pregnant, lactating, or breast-feeding.~* Unwillingness or inability to comply with study and follow-up procedures (i.e. severe anxiety disorder preventing PET/CT imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with BRAF/MEK inhibitor (Type: EXPERIMENTAL): Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.~During the study biopsies and blood will be taken from the patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent obtained prior to study procedures~* Histologically confirmed HCC with serum AFP \>200ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP \>400ng/ml at time of screening and following most current line of therapy..~* Metastatic or locally advanced, unresectable HCC~* Must have failed or not tolerated, at least one line of systemic therapy for advanced HCC~* Molecular Human Leukocyte Antigen (HLA) class I allele typing confirms participant carries at least one HLA-A2 allele~* Life expectancy of at least 4 months~* Karnofsky Performance Scale greater than or equal to 70~* At least 1 measurable lesion on imaging by RECIST~* Child-Pugh A or B7~* Absolute neutrophil count greater than or equal to 1,500/mm\^3~* Platelet count greater than or equal to 30,000/mm\^3~Exclusion Criteria:~* Clinically significant cardiac disease~* Clinically significant pre-existing illness or active infection~* Clinically significant Central Nervous System (CNS) or neural dysfunction~* Active autoimmune disease requiring therapy~* Active malignancy other than HCC unless expected survival is greater than or equal to three years without any treatment (exception: hormone/androgen-depravation therapy) and without any organ involvement~* History of organ transplant~* Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction~* Advanced HCC involving greater than one-third of the liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ET140202 T cells (Type: EXPERIMENTAL): ET140202 Receptor (+) T Cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically confirmed solitary primary or recurrent papillary transitional cell carcinoma of the bladder~  * Ta or T1~* Tumor no greater than 2 cm in diameter~* Negative urine cytology~* No suspicious lesions in bladder requiring biopsy~* No tumors in the prostatic urethra or upper urinary tract~* No prior history of T1 G3 tumors, muscle invasive tumors (T2 or greater), or carcinoma in situ~PATIENT CHARACTERISTICS:~Age~* 80 and under~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* HIV negative~* No active intractable or uncontrollable bladder infection~* No urethral strictures that would preclude endoscopic procedures or repeated catheterization~* No prior or concurrent congenital or acquired immune deficiency syndrome~* No other prior or concurrent malignancy except cured basal cell skin cancer or intraepithelial cancer of the cervix~* No prior or concurrent leukemia or Hodgkin's disease~* No concurrent disease for which general anesthesia is contraindicated~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 12 months since prior BCG vaccine~Chemotherapy~* At least 1 year since prior mitomycin~Endocrine therapy~* Not specified~Radiotherapy~* No prior pelvic radiotherapy~Surgery~* No prior organ transplant~Other~* At least 3 months since prior intravesical treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture and Post-Surgical Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (age \> 18)~* Males/females~* All races~* Elective/urgent CABG~* Open saphenous vein graft harvest~* University of California, San Francisco, and additional approved hospital sites~Exclusion Criteria:~Pre-operative~* Emergent CABG, valves~* History of peripheral vascular surgery, amputation, severe peripheral neuropathy, immunocompromise, or end-stage renal disease requiring hemodialysis~Post-operative~* Postoperative day 1 (POD1) hemodynamic instability~* ≥ 4u packed red blood cells transfusion (PRBC)/8 hours, CT \> 200cc/hour 3 hours, \> 2 pressors~* Prolonged intubation (\> POD1)~* Altered mental status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acupuncture (Type: EXPERIMENTAL): acupuncture to lower extremity postoperatively
- sham acupuncture (Type: SHAM_COMPARATOR): sham acupuncture at same sites.
- control (Type: NO_INTERVENTION): no acupuncture, otherwise the same care and measurements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically or histologically confirmed evidence of epithelial cancer (adenocarcinoma) of the exocrine pancreas~* Metastatic disease~* No prior chemotherapy for pancreatic disease~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2~* Adequate renal, liver and bone marrow functions~Exclusion Criteria:~* Less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of randomization~* Prior treatment with anti-VEGF or VEGF-Receptor-inhibitors~* Uncontrolled hypertension~* Pregnancy or breastfeeding~* Participant with reproductive potential (M/F) without effective method of contraception~The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo and Gemcitabine (Type: PLACEBO_COMPARATOR): Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m\^2 Gemcitabine.
- Aflibercept and Gemcitabine (Type: EXPERIMENTAL): Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m\^2 Gemcitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Neurodevelopmental Outcomes of Preterm and Term Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Born on or after January 1, 2011~* Admitted to the Mount Sinai Hospital for newborn care~Exclusion Criteria:~* Non-English speaking

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 42 Months
- Healthy Volunteers: t

Study Arms:
- Full Term (Type: None): Children born at full term on or after Jan 1, 2011
- PreTerm (Type: None): Children born preterm on or after Jan 1, 2011

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bedside Silo Versus Operative Closure for Gastroschisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with gastroschisis~Exclusion Criteria:~* Born prior to 34 weeks estimated gestational age~* Another congenital anomaly influencing the respiratory status, gastrointestinal status, or the length of hospitalization and recovery.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Day
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Operative attempt at closure
- 2 (Type: EXPERIMENTAL): bedside silo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Metabolomics in Diabetes Patients From Sri Lanka and Switzerland

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes per WHO criteria.~* Swiss ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Switzerland)~* Tamil ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Sri Lanka, belonging to ethnic identity of Tamils, respectively)~* Age limit: 18 - 75 years~Exclusion Criteria:~* Subjects with type 1 diabetes, steroid-induced diabetes, gestation diabetes, or pancreoprivic diabetes.~* Subjects with pregnancy.~* Subjects with metal implant, tattoos, or claustrophobia. MRI must be feasible.~* Subjects with severe chronic diseases, e.g. malignancies, heart or renal diseases (\> stage 3).~* Subjects not able to provide informed consent.~* Enrolled in another study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tamil natives with Diabetes Type 2 (Type: None): Thirty Tamil natives (15 men, 15 women), representing general Tamil diabetic cohort.
- Swiss natives with Diabetes Type 2_matched (Type: None): Thirty Swiss natives (15 men, 15 women) matching the Tamil cohort.
- Swiss natives with Diabetes Type 2_not matched (Type: None): Thirty Swiss natives (15 men, 15 women), who are not matched to the Tamil cohort, representing general Swiss diabetic cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Undergoing Cesarean delivery.~2. Patient at least 18 years of age.~3. Weight greater than 199 pounds.~4. Depth of subcutaneous tissue (measured from fascia to epidermis) of greater than or equal to 4 centimeters.~Exclusion Criteria:~1. Weight less or equal to 199 pounds or less than 4 cm of subcutaneous tissue present.~2. Inability to give proper informed consent.~3. Inability to adhere to follow-up provisions of the study (return for 2 post-operative visits at 7-14 days post-op and between 4-6 weeks post-op).~4. Patient less than 18 years of age.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Negative pressure wound closure (Type: EXPERIMENTAL): Negative Pressure wound closure
- Standard wound closure (Type: ACTIVE_COMPARATOR): Standard Wound Closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Acceptability, and Feasibility of Enterade®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pediatric and caregiver pairs (must meet inclusion criteria for both categories):~Child:~1. Is between 12 and 24 months of age.~2. LAZ between -3 and -1 standard deviations (SD).~3. At least one week post routine immunization, healthy child visit, or vitamin A supplementation visit at the study site.~4. Has a parent or legally acceptable representative willing and able to provide informed consent.~5. No plans for travel outside of the community for the duration of the study.~Caregiver of child:~1. Is a parent or legally accepted representative of a child eligible for this study.~2. Is 18 years of age or older.~3. Has a working mobile phone.~4. Is willing and able to provide informed consent.~5. If illiterate-there is at least one literate adult living in the child's household.~Exclusion Criteria:~Pediatric and caregiver pairs (must meet none of the exclusion criteria for either category):~Child:~1. Has any sign of acute illness, including but not limited to fever, cough, and diarrhea.~2. Is wasted (weight for length z-score \< -2 or mid-upper arm circumference \[MUAC\] \< 12.4 cm) or has pitting edema.~3. Is exclusively breastfed.~4. Is seeking medical attention at the health facility other than for routine, preventative care (e.g., immunization visit, vitamin supplementation).~5. Has suffered within the prior week from illnesses that might impact nutritional status (e.g., severe diarrhea or pneumonia; vomiting; persistent diarrhea; cleft lip or palate; blindness; tuberculosis; jaundice; renal or cardiac disease; cerebral palsy; known metabolic disorders; and chromosomal disorders, including trisomy 21).~6. Medical history of chronic health condition (i.e., HIV, hepatitis B or C, end stage renal disease, severe liver disease-absence of a diagnosis is sufficient).~7. Participating in any other clinical trials.~8. Recent (prior 2 weeks) use of antibiotics or any other medical treatments (including oral re-hydration solution), but not including vaccines or vitamin/mineral supplementation).~9. Cannot give the necessary biological (blood) sample.~Caregiver:~Reports diarrhea in the household in the prior 7 days.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- AA-ORS (Type: EXPERIMENTAL): Those receiving enterade oral re-hydration solution with amino acids
- Placebo (Type: PLACEBO_COMPARATOR): Those receiving placebo solution without amino acids or rehydration salts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previously enrolled as a patient in ST-001 CALISTA study~* Willing to provide written informed consent~* Willing and able to adhere to all study-related procedures~* Willing to authorize release of medical records~* Willing to authorize collection of medical data from health care providers~* Provide email, home address and phone number where he/she can be reached~Exclusion Criteria:~• Patient did not participate in ST-001 CALISTA study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ST-003 Observational (Type: None): Calciphylaxis patients who participated in the ST-001 CALISTA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy